Exosomal small RNA profiling in first-trimester maternal blood explores early molecular pathways of preterm preeclampsia

Front Immunol. 2024 Feb 22:15:1321191. doi: 10.3389/fimmu.2024.1321191. eCollection 2024.

Abstract

Introduction: Preeclampsia (PE) is a severe obstetrical syndrome characterized by new-onset hypertension and proteinuria and it is often associated with fetal intrauterine growth restriction (IUGR). PE leads to long-term health complications, so early diagnosis would be crucial for timely prevention. There are multiple etiologies and subtypes of PE, and this heterogeneity has hindered accurate identification in the presymptomatic phase. Recent investigations have pointed to the potential role of small regulatory RNAs in PE, and these species, which travel in extracellular vesicles (EVs) in the circulation, have raised the possibility of non-invasive diagnostics. The aim of this study was to investigate the behavior of exosomal regulatory small RNAs in the most severe subtype of PE with IUGR.

Methods: We isolated exosomal EVs from first-trimester peripheral blood plasma samples of women who later developed preterm PE with IUGR (n=6) and gestational age-matched healthy controls (n=14). The small RNA content of EVs and their differential expression were determined by next-generation sequencing and further validated by quantitative real-time PCR. We also applied the rigorous exceRpt bioinformatics pipeline for small RNA identification, followed by target verification and Gene Ontology analysis.

Results: Overall, >2700 small RNAs were identified in all samples and, of interest, the majority belonged to the RNA interference (RNAi) pathways. Among the RNAi species, 16 differentially expressed microRNAs were up-regulated in PE, whereas up-regulated and down-regulated members were equally found among the six identified Piwi-associated RNAs. Gene ontology analysis of the predicted small RNA targets showed enrichment of genes in pathways related to immune processes involved in decidualization, placentation and embryonic development, indicating that dysregulation of the induced small RNAs is connected to the impairment of immune pathways in preeclampsia development. Finally, the subsequent validation experiments revealed that the hsa_piR_016658 piRNA is a promising biomarker candidate for preterm PE associated with IUGR.

Discussion: Our rigorously designed study in a homogeneous group of patients unraveled small RNAs in circulating maternal exosomes that act on physiological pathways dysregulated in preterm PE with IUGR. Therefore, our small RNA hits are not only suitable biomarker candidates, but the revealed biological pathways may further inform us about the complex pathology of this severe PE subtype.

Keywords: biomarker; decidualization; early diagnosis; exosome; liquid biopsy; miRNA; piRNA; pregnancy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Female
  • Fetal Growth Retardation / genetics
  • Fetal Growth Retardation / metabolism
  • Humans
  • Infant, Newborn
  • MicroRNAs* / genetics
  • Pre-Eclampsia* / diagnosis
  • Pre-Eclampsia* / genetics
  • Pregnancy
  • Pregnancy Trimester, First

Substances

  • MicroRNAs
  • Biomarkers

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Our research was supported by the grants PC-II-12/2022 and Momentum LP2014-7/2014 of the Hungarian Academy of Sciences, and by the grants ELKH-POC-2022-014 and 2018-1.2.1-NKP-2018-00005. This project was carried out within the Cooperative Doctoral Programme and the New National Excellence Programme and was supported by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under Research Project Codes C1012947 and ÚNKP-20-3-I-ELTE-473, respectively, as well as by the FIEK-16-1-2016-0005, the OTKA-K124862 and the 2019-2.1.7-ERANET-2020-00014 funding schemes, the latter within the framework of the European Union ERA PerMed (grant 2020-346).